H2o Therapeutics

What H2o Therapeutics does

H2o Therapeutics is a privately held, founder-led digital therapeutics company founded in 2014 (some sources cite 2017) and headquartered in Çankaya, Ankara, Turkey, with a US office in Fairfax, Virginia. The company develops prescription digital therapeutics and software-as-a-medical-device (SaMD) solutions targeting neurological and chronic conditions, with Parkinson's disease as its primary therapeutic focus. Its flagship product, Parky, is an Apple Watch-based prescription mobile app that uses Apple's Movement Disorder API to passively monitor motor symptoms — tremors, dyskinesia, steps, and sleep — and generates daily, weekly, and monthly symptom reports correlating motor activity with medication adherence. Parky received FDA 510(k) marketing clearance in November 2022 and EU MDR Class IIa certification in June 2025, positioning it among the few internationally regulated mobile medical apps specifically developed for Parkinson's disease. The company operates under ISO 13485:2016 quality management certification and adheres to IEC 62304:2006 and ISO 14971:2019 standards, with HIPAA and GDPR compliance in place across its US and EU operations.

The platform extends beyond Parky to include the Parky Provider Portal — a web-based interface through which healthcare professionals review patient symptom data, issue prescriptions, and conduct remote monitoring — and a pipeline of two additional digital therapeutics with FDA submissions planned. H2o Therapeutics also offers end-to-to-end digital health development services for partners seeking FDA- and MDR-regulated DTx and SaMD products. The company generates revenue primarily through prescription-based distribution of Parky via healthcare providers and federal procurement channels, with the app listed on the VA Federal Supply Schedule (FSS) and GSA Advantage through its SDVOSB channel partner Lovell Government Services, and broader US commercialization supported by AmerisourceBergen. Founded by Yagmur Selin Gulmus, H2o Therapeutics is explicitly described as woman-founded and non-VC-backed, operating as a small, multi-disciplinary team covering design, development, regulatory, medical, and commercial functions across its Turkish and US offices.

Name

H2o Therapeutics

Legal name

H2O Therapeutics Co.

Website

https://h2otherapeutics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

H2o Therapeutics is a privately held digital therapeutics company that develops FDA-cleared and EU MDR-certified prescription mobile apps, primarily Parky — an Apple Watch-based Parkinson's disease symptom monitoring application — serving patients, neurologists, and federal healthcare systems.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Prescription Digital Therapeutics (PDT) (HLACANAB)

akta.pro secondary industries

Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)

Keywords

• Digital therapeutics
• Prescription mobile apps
• Parkinson's monitoring software
• Wearable health applications
• Medical device software

Headquarters

HQ city

Çankaya

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Prescription Digital Therapeutics: Parky is a prescription mobile app that generates revenue through healthcare provider prescriptions. The app monitors Parkinson's disease symptoms via Apple Watch and delivers reports correlating motor symptoms with medication adherence.
2. Digital Health Solutions Development: Provides end-to-end digital health development services for partners, including regulatory-ready DTx and SaMD solutions for FDA and MDR-regulated markets.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

H2o Therapeutics develops regulatory-ready digital therapeutics and Software as a Medical Device (SaMD) solutions, with its flagship product Parky being an FDA-cleared and EU MDR Class IIa-certified prescription mobile app that uses Apple Watch sensors and Apple's Movement Disorder API to continuously monitor Parkinson's Disease motor symptoms (tremors, dyskinesia) and correlate them with medication adherence. The company also offers the Parky Provider Portal for clinicians and provides end-to-end digital health development services for partners in FDA and MDR-regulated markets.

Product overview

H2o Therapeutics is a digital health company offering turnkey, regulatory-ready digital health solutions with a focus on wearable-integrated software for neurological and chronic conditions. The flagship product is Parky, an FDA-cleared and EU MDR Class IIa certified Apple Watch-based symptom monitoring app for Parkinson's Disease. The company provides comprehensive digital health development services including user-centric mobile applications for Apple devices, seamless API integration with healthcare systems, and full-service development from ideation through commercialization. The product ecosystem includes Parky (core symptom monitoring app), the Parky Provider Portal (healthcare professional interface), and pipeline digital therapeutics products targeting other chronic conditions.

Differentiator

Problem solved

Functional benefit

Brands

• Parky: FDA-cleared, EU MDR-certified Apple Watch-based mobile app for monitoring and managing Parkinson's Disease symptoms, including tremor and dyskinesia, with medication reminders and symptom report generation.

Products and services

• Parky FDA-cleared and EU MDR Class IIa-certified prescription mobile app for Apple Watch that monitors and manages Parkinson's Disease symptoms (tremors, dyskinesia, steps, sleep) in real-time. Provides medication reminders, activity tracking, and generates daily, weekly, and monthly symptom reports correlating motor symptoms with medication adherence for sharing with healthcare professionals.
• Parky Provider Portal Web-based portal for healthcare providers (neurologists and movement disorder specialists) to access patient symptom data, create Parky prescriptions, conduct remote monitoring, and manage care for Parkinson's Disease patients using data collected by the Parky app.
• Digital Health Development Services End-to-end digital health development services for pharmaceutical, healthcare, and medical device partners, including user-centric mobile applications for Apple devices, seamless API integration with healthcare systems, and full-service development from ideation through commercialization for regulatory-ready DTx and SaMD solutions in FDA and MDR-regulated markets.

Quantifiable outcome

• Validated in study of 343 participants with 225 monitored for up to 6 months
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• AmerisourceBergencoreChannel Partner/ Reseller/ Distributor · 24 December 2024Collaboration with AmerisourceBergen to support the commercialization of Apple Watch-Based App Parky for Parkinson's Disease. Leverages AmerisourceBergen's healthcare distribution network for broader market access.
• Lovell Government ServicescoreChannel Partner/ Reseller/ Distributor · 1 September 2024Lovell Government Services serves as h2o Therapeutics' Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve federal healthcare customers including Veterans Health Administration (VHA), Military Health System (MHS), and Indian Health Service (IHS). Parky is available on VA Federal Supply Schedule (FSS) and GSA Advantage, with Lovell streamlining acquisition and helping government agencies fulfill SDVOSB procurement goals.
• Apple Inc.coreTechnology or IntegrationIntegration with Apple's Movement Disorder API for Parkinson's symptom tracking via Apple Watch. The API was validated in a 343-participant study referencing the MDS-UPDRS clinical scale, published in Science Translational Medicine.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Rune Labs: Rune Labs offers StrivePD, a Parkinson's disease management platform using Apple Watch and wearable sensors for motor symptom tracking. Most directly comparable peer given shared Apple Watch-based Parkinson's monitoring focus.
• Akili Interactive: Public prescription digital therapeutics company (EndeavorRx) targeting cognitive and neurological conditions. Comparable as an FDA-cleared, prescription-based digital therapeutic company navigating similar regulatory and reimbursement dynamics.
• Click Therapeutics: Prescription digital therapeutics company developing software-based treatments across neurological and chronic conditions. Comparable business model of prescription DTx with FDA pathway and pharma partnerships.
• Better Therapeutics: Digital therapeutics company developing FDA-regulated prescription software for chronic cardiometabolic conditions. Comparable regulatory and prescription-based DTx model, though targeting different therapeutic areas.

Broad incumbents

• Pear Therapeutics (legacy/Beacon): Historically the leading prescription digital therapeutics company (reSET, reSET-O); assets now under different stewardship. Relevant as a comparable benchmark for the prescription DTx commercialization and reimbursement model.
• WellDoc: Pioneer in chronic-condition digital health (BlueStar for diabetes) with FDA clearance and reimbursement infrastructure. Comparable as an established DTx company building clinician-facing, evidence-based digital therapies for chronic conditions.
• Omada Health: Large-scale virtual care and digital therapeutics company for chronic conditions (diabetes, hypertension, MSK). Comparable as a regulated, evidence-driven digital health company selling to payers, employers, and providers.

Emerging players

• BigHealth: Digital therapeutics company with FDA-cleared products for insomnia (Sleepio) and anxiety. Comparable as a regulated DTx company with prescription/OTC digital therapeutic pathway into chronic conditions.
• Roche/mySugr: mySugr (Roche) provides app-based chronic-condition management for diabetes with regulatory clearances. Comparable as an app-delivered, regulated digital therapeutic for chronic disease sold through healthcare channels.
• Limbic: Digital mental health therapeutic platform with CE-marked software. Comparable as an EU-based digital therapeutic company navigating MDR regulatory pathways and clinical adoption.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/h2otherapeutics

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about H2o Therapeutics